Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 8
Submit an article Journal homepage
1,582
Views
14
CrossRef citations to date
0
Altmetric
Cardiovascular

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands

Marieke HeisenPharmerit International, Rotterdam, The Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5339-6606
ORCID Icon,
Maarten J. TreurPharmerit International, Rotterdam, The Netherlands;
,
Harald E. HeemstraBayer B.V., Mijdrecht, The Netherlands;
,
Eric B. W. GiesenBayer Pharma AG, Berlin, Germany;
&
Maarten J. PostmaUnit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands; ;Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands; ;Institute of Science in Healthy Aging & healthcaRE (SHARE), UMCG, University of Groningen, Groningen, The Netherlands
Pages 813-824 | Received 29 Mar 2017, Accepted 01 May 2017, Published online: 25 Jun 2017

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
Source: Figshare
Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands
Source: Figshare

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.